US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Hls Therapeutics Inc
(TSX:
HLS
)
4.510
-0.050 (-1.10%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Hls Therapeutics Inc
HLS Therapeutics Targets 2027 Growth With Cardiovascular Expansion and New Deals
↗
October 30, 2026
HLS Therapeutics (TSE:HLS) outlined plans to build on its cardiovascular portfolio and pursue additional business-development opportunities as the specialty pharmaceutical company works to translate...
Via
MarketBeat
HLS Therapeutics Q2 Earnings Call Highlights
↗
August 12, 2026
HLS Therapeutics (TSE:HLS) reported second-quarter fiscal 2026 revenue growth as its cardiovascular portfolio expanded 25% year over year, led by continued gains for Vascepa and the first full quarter...
Via
MarketBeat
Topics
Earnings
HLS Therapeutics Q1 Earnings Call Highlights
↗
May 16, 2026
HLS Therapeutics (TSE:HLS) reported modest first-quarter revenue growth and reaffirmed its 2026 outlook, while management highlighted early momentum for the company’s newly launched cholesterol drug...
Via
MarketBeat
Topics
Earnings
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
November 18, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
3 Top Canadian Pharmaceutical Stocks In April 2023
↗
April 15, 2023
When investors discuss striking it rich in the stock market, they often discuss a few industries. One of them being technology and the other being pharmaceutical stocks.
Via
Talk Markets
Sidoti Winter Virtual Small Cap Investor Conference
January 18, 2022
- Presentation Times and Weblinks Released for Over 70 Presenting Companies - Wednesday and Thursday, January 19th-20th, 2022 NEW YORK, NY / ACCESSWIRE / January 18, 2022 / Sidoti & Company, LLC has...
From
Sidoti & Company, LLC
Via
AccessWire
This Pharmaceutical Company Just Got a Major Boost
↗
August 27, 2021
Big-time name recognition could lead to big gains for HLS and its investors.
Via
The Motley Fool
